Stockscreener 앱 받기
1.75
0.00%
0.00
전일 마감가:
$1.75
열려 있는:
$1.76
하루 거래량:
1.33M
Relative Volume:
0.61
시가총액:
$465.75M
수익:
-
순이익/손실:
$-208.38M
주가수익비율:
-1.4583
EPS:
-1.2
순현금흐름:
$-156.57M
1주 성능:
-1.69%
1개월 성능:
-32.95%
6개월 성능:
-10.26%
1년 성능:
-55.81%
1일 변동 폭
$1.745
$1.81
1주일 범위
$1.70
$1.89
52주 변동 폭
$1.105
$5.00
Autolus Therapeutics Plc Adr Stock (AUTL) Company Profile
명칭
Autolus Therapeutics Plc Adr
전화
44 20 3829 6230
주소
THE MEDIAWORKS, LONDON
AUTL을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
AUTL
Autolus Therapeutics Plc Adr
|
1.75 | 500.35M | 0 | -208.38M | -156.57M | -1.20 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Autolus Therapeutics Plc Adr Stock (AUTL) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-11-18 | 업그레이드 | Goldman | Neutral → Buy |
| 2024-11-15 | 업그레이드 | Redburn Atlantic | Neutral → Buy |
| 2023-11-09 | 개시 | Deutsche Bank | Buy |
| 2023-03-27 | 재개 | Wells Fargo | Overweight |
| 2023-03-17 | 개시 | Bryan Garnier | Buy |
| 2021-06-14 | 업그레이드 | Jefferies | Hold → Buy |
| 2021-01-29 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2020-12-28 | 재개 | H.C. Wainwright | Buy |
| 2020-07-31 | 개시 | JP Morgan | Overweight |
| 2020-07-22 | 개시 | SunTrust | Buy |
| 2020-04-22 | 개시 | Mizuho | Buy |
| 2019-09-23 | 개시 | Needham | Buy |
| 2019-05-17 | 재확인 | H.C. Wainwright | Buy |
| 2018-10-24 | 개시 | H.C. Wainwright | Buy |
모두보기
Autolus Therapeutics Plc Adr 주식(AUTL)의 최신 뉴스
Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL) Given Average Recommendation of “Buy” by Brokerages - Defense World
Q3 EPS Forecast for Autolus Therapeutics Raised by Analyst - Defense World
Wells Fargo & Company Has Lowered Expectations for Autolus Therapeutics (NASDAQ:AUTL) Stock Price - Defense World
Cetera Investment Advisers Raises Stock Position in Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL) - Defense World
Autolus Therapeutics (NASDAQ:AUTL) Shares Down 3.5% After Analyst Downgrade - Defense World
Autolus reports $20.9 million in Q2 2025 AUCATZYL revenue - Investing.com India
Will Albertsons Companies Inc. stock recover after recent dropFree Entry and Exit Strategy Optimizer Tool - Newser
Autolus Therapeutics Reports Second Quarter 2025 Financial Results and Business Updates - GlobeNewswire Inc.
How GLDD stock performs during market volatilityAlgorithmic Forecast for Swing Trading Picks - Newser
Why IGNEP stock attracts strong analyst attentionFree Day Trading Signals With High Precision - Newser
When is the best time to buy GRAIL LLC stockFree Smart Allocation Stock Pick Insights - Newser
Is a relief rally coming for Zhibao Technology Inc. holdersSmart Stock Forecast Using AI Algorithms - Newser
Statistical indicators supporting GDV.PRH’s strengthFree Stable Entry High Return Opportunities - Newser
Can machine learning forecast Peoples Bancorp of North Carolina Inc. recoveryHigh Win Rate Strategy with Stop Protection - Newser
What makes Boqii Holding Limited Depositary Receipt stock price move sharplyFree Market Entry and Exit Point Tips - Newser
Autolus Therapeutics plc ADR: Weathering Stock Market Storms with 637.41M Market Cap - investchronicle.com
LyondellBasell Industries NV (LYB) Stock: A Year of Stock Market Ups and Downs - investchronicle.com
Top chart patterns to watch in Stevanato Group S.p.A.Free High Return Stock Focus With Safety - Newser
P 500Real-Time Equity Price Action Analysis - Newser
Unlocking Oncology’s Future: 3 Trending Cancer Biotech Stocks With ‘Strong Buy’ Ratings - Barchart.com
TER’s Stock Market Adventure: -40.87% YTD Growth Amidst Volatility - investchronicle.com
Globe Life Inc (GL) Stock: Navigating a Year of Volatility - investchronicle.com
Autolus Therapeutics’ (AUTL) Buy Rating Reaffirmed at Needham & Company LLC - Defense World
European Commission approves Autolus’ cell therapy for adult leukemia By Investing.com - Investing.com South Africa
European Commission approves Autolus’ cell therapy for adult leukemia - Investing.com India
Will A Mark Precious Metals Inc. stock benefit from interest rate changesDaily Upside Movement Prediction With Data - Newser
Autolus Therapeutics Grants Stock Options to 60 Employees Under 2025 Inducement Plan - Nasdaq
Cambridge Investment Research Advisors Inc. Sells 2,160 Shares of Invesco KBW Property & Casualty Insurance ETF (NASDAQ:KBWP) - Defense World
Allspring Global Investments Holdings LLC Sells 439,622 Shares of Dr. Reddy’s Laboratories Ltd (NYSE:RDY) - Defense World
1,867 Shares in Axsome Therapeutics, Inc. (NASDAQ:AXSM) Bought by DAVENPORT & Co LLC - Defense World
DAVENPORT & Co LLC Trims Holdings in Janus Henderson Short Duration Income ETF (NYSEARCA:VNLA) - Defense World
Vontobel Holding Ltd. Lowers Holdings in Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL) - Defense World
Allspring Global Investments Holdings LLC Raises Holdings in Broadstone Net Lease, Inc. (NYSE:BNL) - Defense World
Wealth Enhancement Advisory Services LLC Takes $258,000 Position in Taylor Morrison Home Corporation (NYSE:TMHC) - Defense World
Vontobel Holding Ltd. Buys 49,643 Shares of Tilray Brands, Inc. (NASDAQ:TLRY) - Defense World
TELUS International (Cda) (TSE:TIXT) Trading 2.1% Higher – What’s Next? - Defense World
Closing Figures: Autolus Therapeutics plc ADR (AUTL)’s Negative Finish at 2.05, Down -3.30 - DWinneX
NOV Inc: Navigating Market Volatility with a 1.79 Debt-to-Equity Ratio - investchronicle.com
Autolus shares surge 77% following InvestingPro’s April Fair Value signal By Investing.com - Investing.com India
EMA committee endorses Autolus’ leukemia therapy obe-cel By Investing.com - Investing.com South Africa
Autolus Therapeutics Gets Favorable Recommendation For Approval Of Cancer Therapy In EU: Retail Sentiment Brightens By Stocktwits - Investing.com India
EMA committee endorses Autolus’ leukemia therapy obe-cel - Investing.com
Autolus Therapeutics plc ADR (AUTL) Has A Gold Mine On Its Hands - Stocksregister
Autolus reports $9M in Q1 product revenue, gains UK approval By Investing.com - Investing.com South Africa
Autolus reports $9M in Q1 product revenue, gains UK approval - Investing.com
AUTL’s Market Whiplash: -44.26% YTD Decline, -21.08% Plunge in 30 Days - investchronicle.com
There is no doubt that Autolus Therapeutics plc ADR (AUTL) ticks all the boxes. - Sete News
Autolus Therapeutics plc ADR (AUTL) receives a Buy rating from Goldman - knoxdaily.com
AUTL’s valuation metrics: A comprehensive analysis - uspostnews.com
Market Resilience: Autolus Therapeutics plc ADR (AUTL) Finishes Weak at 1.33, Down -5.00 - DWinneX
Market Update: Goosehead Insurance Inc (GSHD) Sees Positive Movement, Closing at 99.54 - DWinneX
Autolus Therapeutics Plc Adr (AUTL) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.94%
1.72%
자본화:
|
볼륨(24시간):